Federal health officials announced Wednesday that they have cleared a new liquid medication designed to treat a rare hormone disorder in children, providing families with a more convenient treatment option.
The Food and Drug Administration authorized Eton Pharmaceuticals’ medication called Desmoda, an oral liquid version of desmopressin specifically formulated to treat central diabetes insipidus, also known as arginine vasopressin deficiency. This uncommon condition occurs when the body cannot produce enough of the hormone responsible for controlling water balance, leading to extreme thirst and frequent urination.
Medical experts say the new approval tackles a significant treatment challenge, as physicians must precisely calibrate medication doses to maintain proper fluid levels and prevent harmful changes in sodium concentrations, particularly in young patients.
Company officials project that Desmoda could bring in between $30 million and $50 million in yearly revenue at its peak performance.
